BCRP/ABCG2 inhibitors: a patent review (2009 – present)

Abstract

Introduction: BCRP/ABCG2 is a polyspecific ATP binding cassette transporter involved in multidrug resistance of tumors. Compared with P-glycoprotein/ABCB1 only a few inhibitors are known.

Areas covered: Identification of ABCG2 inhibitors in compound libraries and efforts made to develop new ABCG2 inhibitors are discussed in the review. Additionally, development of new test systems for testing ABCG2 activity and medical applications of ABCG2 inhibitors and activators are reviewed.

Expert opinion: ABCG2 is highly expressed in side-population cells, which possess stem cell properties and are resistant to chemotherapy and radiotherapy. These cells are thought to lead to a relapse after chemotherapy. Therefore, inhibition of ABCG2 could have an additional benefit besides counteracting multidrug resistance. Among the new chemical entities, the bivalent flavonoids seem promising, as selective and broad spectrum inhibitors were found within this class of compounds. However, the available pharmacological data are rather preliminary.

Keywords:

• ABCG2
• ATP binding cassette transporter
• breast cancer resistance protein
• inhibitor

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Notes

This box summarizes key points contained in the article.